Framingham, MA · Founded 2013 · Privately Held (backing)
Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders. Alzheon is based in Framingham, MA and was founded in 2013. Its last reported valuation was $550 million in Apr 2022. It has raised $212 million across 9 recorded rounds; the latest was a $126 million later-stage round in Feb 2024.
Last reported valuation
$550.0M
Oct 2026
Priced at
—
Total raised
$212.2M
Last round
Later Stage VC
Feb 2024
No prints on record
No secondary trades in Alzheon shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Alzheon with a free account
·Watch Alzheon: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Alzheon stock.
